CHAPPAQUA, N.Y., Jan. 16, 2020 /PRNewswire/ — BioTheryX, Inc., a clinical stage biotechnology company creating new classes of compounds based on multi-kinase inhibition and targeted protein degradation, today announced the initiation of patient dosing in its...
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly...
Novotech CRO the largest biotech CRO in the Asia-Pacific said the region has had a record year for number of studies, experienced world-class sites and investigators, and patient enrolment. Novotech, the largest biotech CRO in Asia Pacific, says the region has had a...
Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020 Positive Phase 2 topline data reported for ELX-02 in nephropathic cystinosis from the first treatment...
– Biologics Licensing Application (BLA) submission planned for late 2020 – SAN CARLOS, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer...
– Ongoing BUENA Trial to Continue at Increased Daily Dose – SAINT LAURENT, Quebec, Jan. 15, 2020 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that Health Canada has...
Email
Text